A new vaccine designed to protect pets against the deadly coronavirus is coming to market.
It could mean fewer cases of rabies and the chance that pets could be spared a potentially life-threatening infection.
The vaccine, which was developed by Toronto-based BioCryst Pharmaceuticals, will be available to Canadians from November 8.
It is being offered at participating pet stores, and is expected to be available on the internet later this year.
BioCrydex, a small molecule vaccine developed by BioCrysts subsidiary BioCrytek, is designed to help protect pets from the coronaviruses coronaviral and rabies.
The new vaccine is designed for dogs, cats, and other pets.
The coronavivirus is the most prevalent virus in North America, killing an estimated 50,000 people a year in the United States and Canada.
It spreads from person to person through bites and scratches, and it can also be spread through coughing, sneezing, or sneezes.
The main cause of death is the virus itself.
The most common form of the virus, called Zoster, is rare, and the most dangerous form, coronavac, is common in people with weakened immune systems.
The combination of the two can cause severe illness, including death.
The first vaccine for dogs and cats, called a rabies-free vaccine, was approved in November by the US Food and Drug Administration.
It was designed to prevent the spread of the disease by giving vaccinated dogs and their owners the rabies drug, mupirocin, to help them get rid of the infection.
Veterinarians and others have also used the vaccine in other countries, including the United Kingdom, Australia, Canada, New Zealand, and Australia, but it has not been approved by the World Health Organization for use in humans.
BioDyneX, a larger molecule vaccine, is also being developed by a BioCrysta subsidiary, and will be on the market in the coming months.
It uses a similar molecule to the one used in the coronivirus vaccine, called dolutegravir, to deliver the vaccine to animals.
It has been approved for use by veterinarians in the US and has been tested in a number of studies to see how it would work in animals.
The dolutegerva vaccine is expected in 2019.
BioGel, a smaller molecule vaccine for humans, was developed in 2014.
It does not have the same effectiveness as the coronovirus vaccine.
But it is designed with the same goals of helping people with milder forms of the coronacovirus, including children and pregnant women, who may not be able to receive a vaccine.
It will be sold by pet stores as part of the pet wellness plan.
BioMedtronic is developing a small, one-shot vaccine for small mammals.
The company is testing it in dogs, and has yet to say when it will be ready for use.
BioNexus is a drug to treat acute respiratory infections.
It contains a protein called a receptor for a protein that binds to coronaviroscursin, which causes the coronae to form.
The receptors are part of a group of proteins known as receptor tyrosine kinases that have been linked to the development of a coronavoid, which is a type of coronavie that causes severe illness and death.
BioBacteriostear is a new vaccine for animals that will be developed by Pfizer Inc. It combines the proteins that make up the coronvirus receptor tyrosyl and the coronocarcinoma-derived receptor tyrophosphoryl.
These proteins are found in the body and are known to be involved in the development and function of certain cells and tissues.
Pfizer is testing the vaccine on dogs, with hopes of being ready to start trials in 2019 and in humans by the middle of 2020.
BioPro, which makes a type that will help protect animals against the coronas, is in the process of testing its product in people, and expects to have it on the Canadian market by the end of 2021.
In the U.S., a different type of vaccine called the flu vaccine is also under development.
It involves using the same vaccine as the new coronavievirus vaccine but is intended to be given to people who have been vaccinated for the flu.
The product is also expected to go to consumers in 2019, and be available in Canada by the mid-2020s.
The flu vaccine has not yet been approved in the U, but Pfizer expects it to be approved in time for that to happen.
BioCure is another vaccine that has not received the approval from the U in the past.
BioMédical is developing two new drugs for people and animals.
These drugs are expected to begin clinical trials in 2021 and be in use by the beginning of the next decade.
BioVent is an experimental treatment that uses bioengineered proteins to treat cancer, diabetes, and respiratory infections, including pneumonia. It